On March 9, 2022 Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, reported its participation in the following investor conferences (Press release, Turning Point Therapeutics, MAR 9, 2022, View Source [SID1234609907]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

March 15, 34th Annual Roth Conference, CFO Paolo Tombesi is scheduled to participate in one-on-one meetings.

March 16, Oppenheimer 32nd Annual Healthcare Conference, President and CEO Athena Countouriotis, M.D., is scheduled to present a company overview from 12:40 to 1:10 p.m. ET.

Dr. Countouriotis’ session will be accessible via webcast through the Investors page of www.tptherapeutics.com.